European Addiction Research最新文献

{"title":"ESCAPE Study: Cannabidiol Use in Patients Treated for Substance Use Disorders, Prevalence of Use, and Characteristics of Users.","authors":"Mélanie Duval, Marion Istvan, Morgane Rousselet, Edouard-Jules Laforgue, Marie Grall-Bronnec, Claire Mauriat, Caroline Victorri-Vigneau","doi":"10.1159/000541887","DOIUrl":"10.1159/000541887","url":null,"abstract":"<p><strong>Introduction: </strong>Cannabidiol (CBD) is one of the two primary phytocannabinoids found in cannabis. Its diverse pharmacological properties suggest potential benefits for a wide range of medical conditions. The primary objective of this study was to estimate the prevalence of CBD use among patients being treated for substance use disorder. Additionally, we aimed to characterize the pattern of CBD use and describe the profiles of users.</p><p><strong>Methods: </strong>Patients admitted to two substance use disorder departments between May 6, 2020, and July 23, 2021, were included in the study. Sociodemographic, medical and substance use data, including CBD use, were collected. A multiple correspondence analysis (MCA) was performed to identify substance uses most frequently correlated with CBD use. Multivariate analyses were also conducted to identify factors associated with CBD use.</p><p><strong>Results: </strong>The prevalence of CBD use in the past 12 months among the 183 patients was 38.2%. However, at the time of the study, 63% had stopped using CBD, primarily due to its perceived ineffectiveness and cost. CBD was commonly consumed via inhalation, either by smoking the plant or using e-cigarette liquids. The MCA revealed that while there is no typical profile of CBD users, they were more likely to use sedative substances rather than stimulants. CBD users were younger and more likely to have psychiatric comorbidities.</p><p><strong>Conclusion: </strong>The prevalence of CBD use was notably high. Given the significant risk of drug interactions with CBD and its wide variability in composition, it is crucial for clinicians to routinely inquire about CBD use. The potential for self-therapeutic or recreational use in these patients appears to be underestimated.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"35-46"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Self-Reported Mental Health, Anxiety, and Depression among Patients in Heroin-Assisted Treatment: Findings from a Norwegian Trial Project.","authors":"Lars Henrik Ryther Myklebust, Desiree Eide, Linda Elise C Wüsthoff, Francesca Melis, Ann L Oldervoll, Silvana De Pirro, Thomas Clausen","doi":"10.1159/000547375","DOIUrl":"10.1159/000547375","url":null,"abstract":"<p><strong>Introduction: </strong>Norway's heroin-assisted treatment (HAT) project started in 2022, aimed at targeting individuals with severe opioid use disorder (OUD) who did not benefit from first-line, conventional opioid agonist treatment. The use of pharmaceutical diacetylmorphine in HAT may particularly benefit patients with comorbid psychiatric disorders due to its structured nature, which includes daily contact with outpatient clinics. However, previous findings on mental health outcomes in HAT have been inconclusive. The main aim of this study was to explore changes in patients' self-rated mental health and anxiety and depression over the first 12 months of HAT in Norway.</p><p><strong>Methods: </strong>We used data from 2 questions about patients' self-rated mental health and anxiety and depression collected from 79 patients at the start of treatment (baseline) and at 3, 6, and 12 months into treatment. Ordinal logistic regression models were used to examine the changes in the responses over the observational period and to explore the potential effects of predictors such as gender and age, self-reported substance use, and clinic site.</p><p><strong>Results: </strong>We found a gradual improvement in self-rated mental health from baseline over the observational period, with a statistically significant shift in response distribution at the 12-month mark (p = 0.017). The distribution of responses indicating \"good\" mental health increased with a 35% improvement at 12 months, with a corresponding decline of 48% in \"bad\" mental health. For self-rated anxiety and depression, we found no change in severity of self-rated symptoms. A decline of 48% in the proportion of responses reporting severe symptoms at 12 months was aligned with a simultaneous increase of 17% reporting moderate symptoms. Age and previous suicide attempts were significant predictors of both outcomes; gender influenced anxiety and depression only, whereas clinic site influenced only mental health ratings.</p><p><strong>Conclusion: </strong>HAT appears to gradually improve patients' self-rated mental health over time, possibly by enhancing overall psychological well-being. Self-rated symptoms of anxiety and depression may not be affected by this treatment, indicating that psychiatric conditions can persist in HAT for those struggling with them. This highlights the importance of specific psychiatric assessments and targeted interventions for at least a subset of patients, underscoring the need for integrated treatment approaches within HAT programs that address both substance use and co-occurring psychiatric disorders.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"286-296"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diversion of Diacetylmorphine in Heroin-Assisted Treatment: A Focus Group Study among Patients and Treatment Providers.","authors":"Elisabeth Strickler, Zacharias Wicki, Jean N Westenberg, Johannes Strasser, Undine E Lang, Kenneth M Dürsteler, Maximilian Meyer, Marc Vogel","doi":"10.1159/000545162","DOIUrl":"10.1159/000545162","url":null,"abstract":"<p><strong>Introduction: </strong>Heroin-assisted treatment (HAT) involves the supervised administration of pharmaceutical heroin (diacetylmorphine; DAM), either injectable or oral, for individuals with severe opioid use disorder who have not achieved stabilisation with conventional opioid agonist treatment. Despite its growing adoption, there is limited literature on the phenomenon of diversion in HAT. Diversion refers to the redirecting of legal prescription medications from their intended medical use to illegal or unauthorised use. This study aimed to investigate the reasons for, experiences with, and consequences of DAM diversion, as reported by both patients and treatment providers.</p><p><strong>Methods: </strong>In this qualitative study, two separate focus groups were conducted with patients and treatment providers (nurses, psychiatrists, social workers, and psychologists), respectively. Discussions were audio-recorded, transcribed, and analysed. Mayring's qualitative content analysis was used to evaluate the findings.</p><p><strong>Results: </strong>Five themes with fourteen categories emerged. Providers and patients both described procedures and motives of diversion, discussed the positive and negative consequences, and suggested solutions for reduced future diversion of DAM. An important motif for diversion stemmed from patients' urge for more autonomy over route, timing, and fractioning of administration, while also being used to finance concurrent cocaine use. Treatment providers and patients both noted that diversion may lead to increased overdose risk for individuals in and out of treatment. Nurses noted a substantial negative impact of diversion on the therapeutic relationship. Suggestions for reducing diversion included allowing for more take-home dosing, allowing for more flexibility in routes of administration, adapting HAT clinic opening hours, and providing effective treatment for cocaine use disorder.</p><p><strong>Conclusion: </strong>The main drivers of diversion in HAT included a desire for more autonomy, unaddressed concurrent substance use, and significant barriers to the existing treatment options. Addressing patients' preferred opioid effect profile, accommodating their social needs, and managing concurrent cocaine use disorders may reduce diversion in the future.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"87-98"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Associations between Cannabis Prices, Stores, and Usage after Recreational Legalization.","authors":"Michael J Armstrong","doi":"10.1159/000544104","DOIUrl":"10.1159/000544104","url":null,"abstract":"<p><strong>Introduction: </strong>Canada legalized recreational cannabis in October 2018, but commercial retailing took time to develop. This study first explored how self-reported cannabis use prevalence, daily use, product type use, and age of initial use changed during 2019-2023. It then analyzed whether the changes were associated with rising store numbers or falling prices.</p><p><strong>Methods: </strong>Data on store counts, retail pricing, and cannabis use came from government reports covering 10 provinces over 5 years. Panel data linear regressions analyzed 50 province-year aggregated observations.</p><p><strong>Results: </strong>There were no significant changes in prevalence among males and people aged 16-24 or in the proportion using cannabis daily. Prevalence among females and people aged 25+ increased; those levels showed negative associations with prices but not stores. Dried cannabis use decreased, while edibles use increased; those also showed associations with prices but not stores. Mean initial age of use increased; it was negatively associated with prices and positively with stores.</p><p><strong>Conclusion: </strong>Canada's large cannabis retail expansion was accompanied by relatively modest usage changes, most of which showed associations with falling prices but not rising store counts.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"125-132"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Inhibition-Related Brain Function and Psychological Flexibility during Smoking Abstinence: A Machine-Learning Prediction of Time to Relapse.","authors":"Louis-Ferdinand Lespine, Laura M Rueda-Delgado, Nigel Vahey, Kathy L Ruddy, Hanni Kiiski, Nadja Enz, Rory Boyle, Laura Rai, Gabi Pragulbickaite, Jonathan B Bricker, Louise McHugh, Robert Whelan","doi":"10.1159/000546112","DOIUrl":"10.1159/000546112","url":null,"abstract":"<p><strong>Introduction: </strong>Despite substantial health benefits, smoking cessation attempts have high relapse rates. Neuroimaging measures can sometimes predict individual differences in substance use phenotypes - including relapse - better than behavioral metrics alone. No study to date has compared the relative prediction ability of changes in psychological processes across prolonged abstinence with corresponding changes in brain activity.</p><p><strong>Methods: </strong>Here, in a longitudinal design, measurements were made 1 day prior to smoking cessation, and at 1 and 4 weeks post-cessation (total n = 120). Next, we tested the relative role of changes in psychosocial variables versus task-based functional brain measures predicting time to nicotine relapse up to 12 months. Abstinence was bio-verified 4-5 times during the first month. Data were analyzed with a novel machine-learning approach to predict relapse.</p><p><strong>Results: </strong>Results showed that increased electrophysiological brain activity during inhibitory control predicted longer time to relapse (c-index = 0.56). However, reward-related brain activity was not predictive (c-index = 0.45). Psychological variables, notably an increase during abstinence in psychological flexibility when experiencing negative smoking-related sensations, predicted longer time to relapse (c-index = 0.63). A model combining psychosocial and brain data was predictive (c-index = 0.68). Using a best-practice approach, we demonstrated generalizability of the combined model on a previously unseen holdout validation dataset (c-index = 0.59 vs. 0.42 for a null model).</p><p><strong>Conclusion: </strong>These results show that changes during abstinence - increased smoking-specific psychological flexibility and increased inhibitory control brain function - are important in predicting time to relapse from smoking cessation. In the future, monitoring and augmenting changes in these variables could help improve the chances of successful nicotine smoking abstinence.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"99-112"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Motivational Interviewing in Addiction Services: An Exploratory Study of Training Needs.","authors":"Nuri Wieland, Helle Larsen, Reinout W Wiers, Julia Kühling, Wiebke Brunner, Ulrich Frischknecht","doi":"10.1159/000546243","DOIUrl":"10.1159/000546243","url":null,"abstract":"<p><strong>Introduction: </strong>The effectiveness of Motivational Interviewing (MI) in addiction treatment has been proven many times. Many national treatment guidelines throughout the EU recommend MI as a method in the treatment of addiction-related and comorbid disorders. However, little is known on the availability of workforce that is able to provide sufficiently quality-secured MI. The aim of this study was to investigate the level of training and the use of MI among addiction care professionals in Germany.</p><p><strong>Methods: </strong>In a quantitative, anonymous cross-sectional survey, 262 professionals from the addiction care system were asked about their training in MI, their level of knowledge, the motivation of their clients, and the use of MI in practice. All data analyses were carried out using SPSS.</p><p><strong>Results: </strong>Among the professionals, 54.8% (n = 143) reported having had at least 1 day of training in MI. 64.3% (n = 90) of the trained professionals felt sufficiently trained for their area of responsibility. 31.0% (n = 83) of the total sample stated that further training, quality circles, training courses, or similar had been set up at their facility. Results of an ordinal logistic regression indicated that the use of MI in practice could be predicted by MI-specific training (OR = 0.23, 95% CI = 0.13-0.38, p < 0.01) and the availability of MI support structures in the institution (OR = 0.48, 95% CI = 0.28-0.81, p < 0.01).</p><p><strong>Conclusions: </strong>The results suggest a divergence between medical treatment recommendations for the use of MI and the level of training required for this in the German addiction treatment landscape.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"169-178"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics-Driven Individualized Detoxification Procedure in Patients Dependent on Benzodiazepines and Other GABA-A Receptor Modulators.","authors":"Anna R Basińska-Szafrańska","doi":"10.1159/000547221","DOIUrl":"10.1159/000547221","url":null,"abstract":"<p><strong>Introduction: </strong>Despite extreme inter-patient differences in the benzodiazepine (BZD) metabolism rate, patients dependent on BZDs or other GABA-A receptor modulators are treated without laboratory control. The proposed detoxification method is the first to employ concentration feedback to prevent routinely unrecognized problems: overaccumulation of a long-acting BZD substitute, high concentration upon discontinuation (mimicking patients' adaptation to \"abstinence\"), elimination continuing long after treatment conclusion, resulting in delayed low-concentration crises and relapses of drug intake.</p><p><strong>Methods: </strong>A new method, although evolved from a typical gradual dose reduction approach, is driven not by a dosage schedule but by an individual BZD concentration evolution. This defines four treatment stages: Substitution, anti-accumulation paradigm, elimination, and readaptation (SAER). The S stage, substitution by titration (using diazepam or clorazepate, well read by immunoassays) ends with achieving a satiation state and establishing individual clinical state and concentration baselines. During the A stage, to minimize further (unneeded) accumulation, doses are aggressively reduced daily, driven by concentration feedback, until accumulation ceases (a quasi-plateau). Further tapering opens the E stage (actual detoxification), hence slows, depending on the patient's condition and elimination rate, and concentration is tracked with lower frequency (every 3-7 days), including after drug discontinuation. Only after complete elimination (R stage), patients adapt to true abstinence.</p><p><strong>Conclusions: </strong>The SAER approach can minimize overaccumulation-related errors. The use of serum-BZD feedback curbs the initial overaccumulation. A forced concentration plateau establishes optimized initial conditions for the elimination process. By minimizing a superfluous high-concentration treatment phase, SAER provides more time for careful escorting of the low-concentration crises, especially the one coinciding with elimination completion, weeks after drug discontinuation. Without extending the usual treatment time, the method aspires to improve both the reliability of the detoxification process and the treatment completion rate.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"264-273"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose Intake Reduces Craving in Patients with Alcohol Use Disorder Depending on Insulin Response.","authors":"Lea Wetzel, Sabine Hoffmann, Iris Reinhard, Alisa Riegler, Madeleine Pourbaix, Isabel Ardern, Tobias Link, Sabine Vollstädt-Klein, Bernd Lenz, Falk Kiefer, Anne Koopmann, Patrick Bach","doi":"10.1159/000546648","DOIUrl":"10.1159/000546648","url":null,"abstract":"<p><strong>Introduction: </strong>There is evidence that the appetite-regulating hormone insulin plays an important role in alcohol use disorder (AUD), in the sense that there is a negative correlation between insulin and alcohol craving, meaning that an increase in insulin levels leads to a reduction in acute craving. This suggests a promising approach for the acute reduction of craving in the treatment of patients with AUD, which could be achieved via an actively induced short-term increase in insulin levels, e.g., by glucose administration, and which has not yet been investigated in the form of a randomized controlled trial. Another aspect that has not yet been investigated is the role of the insulin-responder-type of each individual, i.e., the time until the insulin peak is reached, in this relationship.</p><p><strong>Methods: </strong>The randomized, placebo-controlled, double-blind crossover study examined a glucose intake as acute treatment to reduce craving in 80 male and female patients with AUD. Dynamics in craving and insulin levels were assessed at 8 time points on each study visit before and after alcohol cue exposure, after treatment with glucose-respective placebo solution and during the subsequent observation phase. These changes were analyzed using linear mixed models. The insulin-responder-type (fast, normal, slow) of each person was taken into account, and possible interactions with the treatment were analyzed.</p><p><strong>Results: </strong>Linear mixed models revealed a significant interaction effect (F(2, 412.058) = 7.988, p < 0.001) between treatment and insulin-responder-type on craving, with lower craving values in the glucose compared to the placebo condition in the normal insulin-responder-type group (i.e., insulin peak after glucose intake within 30 to 60 min, difference in means = -0.805, p = 0.003, 95% CI: -1.428, -0.182). In the contrary, in the fast insulin-responder-type group craving values were higher in the glucose compared to the placebo condition (difference in means = 1.143, p = 0.011, 95% CI: 0.378, 1.907). Slow insulin-responders showed no differences in craving levels depending on the treatment condition (difference in means = -0.124, p = 0.694, 95% CI: -0.741, 0.493). No main effect was found in the linear mixed models for baseline-centered insulin levels (F(1, 395.337) = 2.328, p = 0.128).</p><p><strong>Conclusions: </strong>Glucose intake may reduce craving in individuals with AUD who show a normal insulin response. Further research should consider the different insulin-responder-types and peak times to better understand the underlying mechanisms of craving reduction with glucose administration in the context of insulin elevation.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"251-263"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Evaluation of the Dutch Version of the Substance Use Recovery Evaluator (SURE-NL).","authors":"Charlotte Migchels, Wim van den Brink, Amine Zerrouk, Frieda I A Matthys, Clara De Ruysscher, Dries Debeer, Wouter Vanderplasschen, Cleo Lina Crunelle","doi":"10.1159/000541584","DOIUrl":"10.1159/000541584","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Patient-reported outcome measures (PROMs) are an important source of information that allow for a patient-centered assessment. Outcome measurement of substance use disorder (SUD) treatment traditionally focuses on drug use and deficits in functioning, overlooking other aspects of the personal and dynamic process of recovery. The substance use recovery evaluator (SURE) is a PROM developed with service user input to monitor the recovery journey and assess treatment outcomes in people with SUD. The objective of this study was to examine the validity and reliability of the Dutch translation of the SURE, the SURE-NL, for measuring indicators of recovery in Dutch-speaking patients with SUD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The original SURE questionnaire was translated from English to Dutch using forward-backward translation. A total of N = 171 participants were recruited as part of a naturalistic multicenter study in inpatient (N = 149) and outpatient (N = 22) SUD treatment centers. We examined the factorial structure, reliability, and concurrent and discriminant validity of the SURE-NL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The original 5-factor structure of the SURE showed acceptable fit for the SURE-NL, and internal consistencies of the subscales ranged from 0.61 to 0.76; internal consistency of the total score was 0.83. Concurrent validity was confirmed through positive correlations of the SURE-NL total and subscale scores with the WHOQoL-BREF subscales, but correlations varied depending on subscale and treatment setting, with higher correlations for the outpatient compared to the inpatient subgroup. Discriminant validity was confirmed through low, mostly non-significant correlations between the SURE-NL and the DASS-21.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Although the SURE was originally designed for outpatient settings, our findings in a predominantly inpatient sample indicate that the SURE-NL is suitable for assessing personal recovery and recovery capital in Dutch-speaking Belgian patients with SUD. However, subscales should be used and interpreted with caution. Further research is needed with larger Dutch-speaking outpatient samples and the development of a tailored SURE for inpatient settings should be considered.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Patient-reported outcome measures (PROMs) are an important source of information that allow for a patient-centered assessment. Outcome measurement of substance use disorder (SUD) treatment traditionally focuses on drug use and deficits in functioning, overlooking other aspects of the personal and dynamic process of recovery. The substance use recovery evaluator (SURE) is a PROM developed with service user input to monitor the recovery journey and assess treatment outcomes in people with SUD. The objective of this study was to examine the validity and reliability of the Dutch translation of the SURE, the SURE-NL, for measuring indicators of recovery in Dutch-speaking pat","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"13-22"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Machine Learning-Based Adjustments to an eHealth Intervention Targeting Mild Alcohol Use.","authors":"Marloes Derksen, Max van Beek, Matthijs Blankers, Hamed Nasri, Tamara de Bruijn, Nick Lommerse, Guido van Wingen, Steffen Pauws, Anna E Goudriaan","doi":"10.1159/000543252","DOIUrl":"10.1159/000543252","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate effects of three machine learning based adjustments made to an eHealth intervention for mild alcohol use disorder, regarding (a) early dropout, (b) participation duration, and (c) success in reaching personal alcohol use goals. Additionally, we aimed to replicate earlier machine learning analyses.</p><p><strong>Methods: </strong>We used three cohorts of observational log data from the Jellinek Digital Self-help intervention. First, a cohort before implementation of adjustments (T0; n = 320); second, a cohort after implementing two adjustments (i.e., sending daily emails in the first week and nudging participants towards a \"no alcohol use\" goal; T1; n = 146); third, a cohort comprising the prior adjustments complemented with eliminated time constraints to reaching further in the intervention (T2; n = 236).</p><p><strong>Results: </strong>We found an increase in participants reaching further in the intervention, yet an increase in early dropout after implementing all adjustments. Moreover, we found that more participants aimed for a quit goal, whilst participation duration declined at T2. Intervention success increased, yet not significantly. Lastly, machine learning demonstrated reliability for outcome prediction in smaller datasets of an eHealth intervention.</p><p><strong>Conclusion: </strong>Strong correlates as indicated by machine learning analyses were found to affect goal setting and use of an eHealth program for alcohol use problems.</p>","PeriodicalId":11902,"journal":{"name":"European Addiction Research","volume":" ","pages":"47-59"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}